PDF(Pubmed)
Abstract：
Aim: Ursolic acid (UA) has an important biological role in the fight against fat accumulation, insulin resistance, obesity and inflammation. Therefore, in the current review and meta-analysis work, we investigate the effects of UA (dosage range is 50.94 to 450 mg/day) on cardiometabolic risk factors. Materials & methods: After searching the studies up to February 2023, six articles were included in the study. Results: The pooled effect size showed that UA supplementation didn\'t significantly change body weight, body mass index, waist circumference, body fat percentage, lean body mass, systolic blood pressure, diastolic blood pressure, fasting blood glucose, insulin, triglyceride and high-density lipoprotein compared with control groups. Conclusion: UA supplementation had no significant effect on the cardiometabolic risk factors in adults.
Cardiovascular disease (CVD) is a significant reason for morbidity and mortality. Ursolic acid (UA) has been shown to play important biological roles in the fight against fat accumulation, oxidative stress, insulin resistance via insulin-like growth factor 1, cancer, muscle atrophy, obesity and inflammation responsible for CVD. A systematic review and meta-analysis were conducted up to February 2023; six articles were included in the study and eleven cardiometabolic risk factors were identified. The pooled effect size showed that UA supplementation (dosage range is 50.94 to 450 mg/day) didn\'t significantly change body weight, body mass index, waist circumference, body fat percentage, lean body mass, systolic blood pressure, diastolic blood pressure, fasting blood glucose, insulin, triglyceride, and high-density lipoprotein compared with control groups.
Cardiovascular disease (CVD) is a significant reason for morbidity and mortality. Ursolic acid (UA) has been shown to play important biological roles in the fight against fat accumulation, oxidative stress, insulin resistance via insulin-like growth factor 1, cancer, muscle atrophy, obesity and inflammation responsible for CVD. A systematic review and meta-analysis were conducted up to February 2023; six articles were included in the study and eleven cardiometabolic risk factors were identified. The pooled effect size showed that UA supplementation (dosage range is 50.94 to 450 mg/day) didn\'t significantly change body weight, body mass index, waist circumference, body fat percentage, lean body mass, systolic blood pressure, diastolic blood pressure, fasting blood glucose, insulin, triglyceride, and high-density lipoprotein compared with control groups.
摘要：
目的：熊果酸（UA）在对抗脂肪积累方面具有重要的生物学作用，胰岛素抵抗，肥胖和炎症。因此,在当前的审查和荟萃分析工作中，我们研究了UA(剂量范围为50.94~450mg/d)对心脏代谢危险因素的影响.材料与方法：在搜索截至2023年2月的研究后，该研究包括六篇文章。结果：汇总效应大小显示补充UA没有显著改变体重，身体质量指数,腰围,身体脂肪百分比，瘦体重,收缩压,舒张压,空腹血糖,胰岛素，甘油三酯和高密度脂蛋白与对照组比较。结论：补充UA对成人心脏代谢危险因素无明显影响。
心血管疾病(CVD)是发病率和死亡率的重要原因。熊果酸（UA）已被证明在对抗脂肪积累的斗争中发挥重要的生物学作用，氧化应激，胰岛素抵抗通过胰岛素样生长因子1，癌症，肌肉萎缩,肥胖和炎症是CVD的原因。直到2023年2月进行了系统评价和荟萃分析；该研究包括六篇文章，并确定了11个心脏代谢危险因素。汇总效应大小显示，UA补充剂（剂量范围为50.94至450毫克/天）没有显着改变体重，身体质量指数,腰围,身体脂肪百分比，瘦体重,收缩压,舒张压,空腹血糖,胰岛素，甘油三酯，和高密度脂蛋白与对照组比较。
心血管疾病(CVD)是发病率和死亡率的重要原因。熊果酸（UA）已被证明在对抗脂肪积累的斗争中发挥重要的生物学作用，氧化应激，胰岛素抵抗通过胰岛素样生长因子1，癌症，肌肉萎缩,肥胖和炎症是CVD的原因。直到2023年2月进行了系统评价和荟萃分析；该研究包括六篇文章，并确定了11个心脏代谢危险因素。汇总效应大小显示，UA补充剂（剂量范围为50.94至450毫克/天）没有显着改变体重，身体质量指数,腰围,身体脂肪百分比，瘦体重,收缩压,舒张压,空腹血糖,胰岛素，甘油三酯，和高密度脂蛋白与对照组比较。
